						1			
	I.1. Consignor				I.2. IMSOC reference	I.2.a. Local reference			
	Name					I.3. Central Competent Authority			
	Address								
	Country		ISO Code			I.4. Local Competent Authority			
Ŀ	I.5. Consignee				I.6. Operator conducting assembly	operations independently of an			
len	Name				establishment				
E	Address				Name				
. <mark>6</mark>	Country		ISO Code		Address Approval Number				
ä					Country	ISO Code			
Ŭ									
	I.7. Country of orig	gin		ISO Code	I.9. Country of destination	ISO Code			
Part I: Description of consignment	I.8. Region of origi			Code	I.10. Region of destination	Code			
Ē				Code		Coue			
SC	I.11. Place of dispa	itch			I.12. Place of destination				
å	Name				Name				
Ë	Address Approval Number	r			Address Approval Number				
ar	Country	L	ISO Code		Approval Number Country ISO Code				
입	-				-				
	I.13. Place of loadi	ng			I.14. Date and time of departure				
	Name Address								
	Approval Number	r							
	Country	L	ISO Code						
	-								
	I.15. Means of Tra	-	Identification		I.16. Transporter				
	Mode	International transport	Identification		Name				
		document			Address Activity ID				
					Country	ISO Code			
					I.17. Accompanying documents				
					Accompanying document reference				
					Date of issue				
					Country				
	I 19 Transport co	aditions			Place of issue				
	I.18. Transport cor	nditions	Chille			1			
	I.18. Transport cor Ambient 🗖	nditions	Chille	ed 🗆	Place of issue	]			
	-		Chille	ed 🗆		]			
	Ambient 🗆		Chille	ed 🗆		]			
	Ambient 🗆 I.19. Container No	/ Seal No	Chille Confined establisi			]			
	Ambient  I.19. Container No I.20. Certified as Further keeping	/ Seal No	Confined establish		Frozen 🗆	]			
	Ambient  I.19. Container No I.20. Certified as Further keeping	/ Seal No	Confined establish		Frozen 🗆	]			
	Ambient I.19. Container No I.20. Certified as Further keeping I.21. For transit th Third country	/ Seal No	Confined establish		Frozen Exhibition ISO Code	]			
	Ambient I.19. Container No I.20. Certified as Further keeping I.21. For transit th Third country Exit point	/ Seal No	Confined establish		Exhibition	]			
	Ambient  I.19. Container No I.20. Certified as Further keeping  I.21. For transit th Third country Exit point Entry point	/ Seal No	Confined establish try		Exhibition				
	Ambient  I.19. Container No I.20. Certified as Further keeping  I.21. For transit th Third country Exit point Entry point	/ Seal No	Confined establish try		Exhibition				
	Ambient  I.19. Container No I.20. Certified as Further keeping  I.21. For transit th Third country Exit point Entry point	/ Seal No	Confined establish try		Frozen Exhibition ISO Code BCP code BCP code I.23. For export Third country	ISO Code			
	Ambient I.19. Container No I.20. Certified as Further keeping I.21. For transit th Third country Exit point Entry point I.22. For transit th Member State	/ Seal No	Confined establish try te(s)		Exhibition   Exhibition   ISO Code BCP code BCP code I.23. For export Third country Exit point				
	Ambient I.19. Container No I.20. Certified as Further keeping I.21. For transit th Third country Exit point Entry point I.22. For transit th	/ Seal No	Confined establish try te(s)		Frozen Exhibition ISO Code BCP code BCP code I.23. For export Third country	ISO Code			
	Ambient I.19. Container No I.20. Certified as Further keeping I.21. For transit th Third country Exit point Entry point I.22. For transit th Member State	/ Seal No ] rough a third coun rough Member Sta	Confined establish try te(s)		Exhibition   Exhibition   ISO Code BCP code BCP code I.23. For export Third country Exit point	ISO Code			
	Ambient I.19. Container No I.20. Certified as Further keeping I.21. For transit th Third country Exit point Entry point I.22. For transit th Member State I.24. Estimated jou	/ Seal No	Confined establish try te(s)		Frozen Exhibition ISO Code BCP code BCP code I.23. For export Third country Exit point I.25. Journey Log	ISO Code			
	Ambient I.19. Container No I.20. Certified as Further keeping I.21. For transit th Third country Exit point Entry point I.22. For transit th Member State I.24. Estimated jou I.27. Total quantity	/ Seal No  rough a third coun rough Member Sta urney time y f consignment	Confined establish try te(s)		Frozen Exhibition ISO Code BCP code BCP code I.23. For export Third country Exit point I.25. Journey Log	ISO Code			
	Ambient 1.19. Container No 1.20. Certified as Further keeping 1.21. For transit th Third country Exit point Entry point 1.22. For transit th Member State 1.24. Estimated jou 1.27. Total quantity 1.30. Description o <b>1.01</b> LIVE ANIMA	/ Seal No  / Seal No  rough a third coun rough Member Sta urney time / f consignment LS	Confined establish try te(s)		Frozen Exhibition ISO Code BCP code BCP code I.23. For export Third country Exit point I.25. Journey Log	ISO Code			
	Ambient I.19. Container No I.20. Certified as Further keeping I.21. For transit th Third country Exit point Entry point I.22. For transit th Member State I.24. Estimated jou I.27. Total quantity I.30. Description o	/ Seal No  / Seal No  rough a third coun rough Member Sta urney time / f consignment LS	Confined establish try te(s)		Frozen Exhibition ISO Code BCP code BCP code I.23. For export Third country Exit point I.25. Journey Log	ISO Code			
	Ambient 1.19. Container No 1.20. Certified as Further keeping 1.21. For transit th Third country Exit point Entry point 1.22. For transit th Member State 1.24. Estimated jou 1.27. Total quantity 1.30. Description o <b>1. 01</b> LIVE ANIMA <b>0106</b> Other live	/ Seal No  / Seal No  rough a third coun rough Member Sta urney time / f consignment LS animals	Confined establish try te(s)		Frozen Exhibition ISO Code BCP code BCP code I.23. For export Third country Exit point I.25. Journey Log	ISO Code			
	Ambient 1.19. Container No 1.20. Certified as Further keeping 1.21. For transit th Third country Exit point Entry point 1.22. For transit th Member State 1.24. Estimated jou 1.27. Total quantity 1.30. Description o 1. 01 LIVE ANIMA 0106 Other live Birds: 010631 Bir 0106310	/ Seal No  / Seal No  rough a third coun  rough Member Sta  urney time  / f consignment LS animals ds of prey 0 Birds of prey	Confined establish try te(s) ISO Code		Frozen Exhibition ISO Code BCP code I.23. For export Third country Exit point I.25. Journey Log I.28. Total gross weight	ISO Code BCP code			
	Ambient 1.19. Container No 1.20. Certified as Further keeping 1.21. For transit th Third country Exit point Entry point 1.22. For transit th Member State 1.24. Estimated jou 1.27. Total quantity 1.30. Description o 1. 01 LIVE ANIMA 0106 Other live Birds: 010631 Bir	/ Seal No  / Seal No  rough a third coun  rough Member Sta  urney time  / f consignment LS animals ds of prey 0 Birds of prey	Confined establish try te(s)		Frozen Exhibition ISO Code BCP code I.23. For export Third country Exit point I.25. Journey Log I.28. Total gross weight	ISO Code BCP code			
	Ambient 1.19. Container No 1.20. Certified as Further keeping 1.21. For transit th Third country Exit point Entry point 1.22. For transit th Member State 1.24. Estimated jou 1.27. Total quantity 1.30. Description o 1. 01 LIVE ANIMA 0106 Other live Birds: 010631 Bir 0106310	/ Seal No  / Seal No  rough a third coun  rough Member Sta  urney time  / f consignment LS animals ds of prey 0 Birds of prey	Confined establish try te(s) ISO Code		Frozen Exhibition ISO Code BCP code I.23. For export Third country Exit point I.25. Journey Log I.28. Total gross weight	ISO Code BCP code			

_	KOI LAN					establistilleri					
	II. Health info	ormation									
	I, the unde	rsigned offi	cial veterin	arian, hereb	t:						
	II.1.	.The anima	als(1) in the	consignmen	nt described i	n Part I meet the following r	requirements:				
		II.1.1.		ïned establi ion (EU) 201		spatch is approved in accord	ance with Articles 97 and 99				
r al l II. Cel ull'autol		II.1.2.	listed in An examination	nnex of Com on, or wher 48 hour per	nmission Imp e this is not p	s or symptoms of diseases, in particular relevant diseases plementing Regulation (EU) 2018/1882, during the clinical possible, a clinical inspection, which was carried out departure of the consignment, on (insert					
מדרדי	II.2.	-	to official in uirements:	o official information, animals in the consignment described in Part I meet the following irements:							
ÿ		II.2.1.			fined establis to be moved.	shment that is not subject to	movement restrictions				
	(2)(3) 🗆 either	[II.2.2.	(serotypes	1-24), wher	e no case of i	•	rus (serotypes 1-24) has beer				
			vaccinated 60 day per	l with a live riod before t	vaccine agai he date of mo	ns in the targeted animal pop nst infection with bluetongu ovement and the requirement Commission Delegated Reg	e virus (serotypes 1-24) in th nts laid down in Article				
	(2)(3) 🗆 and/or	[II.2.2.	infection v	ey originate from a Member State or a zone covered by the eradication programme for fection with bluetongue virus (serotypes 1-24) and the requirements laid down in Article (1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 are fulfilled, and							
	(2)	□ either	[II.2.2.1.	bluetongu	-		ly free from infection with h Article 40(3) of Commissio				
		(2)	🗆 either	[II.2.2.1.1.	for at least (	50 days prior to the date of n	novement]]				
		(2)	□ and/or		for at least 2 subjected to samples col animal into	28 days prior to the date of n a serological test, with nega lected at least 28 days follow	novement and have been ative results, carried out on ring the entry date of the easonally free from infectior				
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at the Member	•	sults, carried out on samples entry date of the animal into				
	(2)	□ and/or	[II.2.2.2.	place of de			during transportation to the gainst attacks by vectors in a				
		(2)	🗆 either	[II.2.2.2.1.	for at least (	60 days prior to the date of n	novement]] .				
		(2)	□ and/or	[II.2.2.2.2.	subjected to samples col	28 days prior to the date of n a serological test, with nega lected at least 28 days follow nent of the period of protect	tive results, carried out on ring the date of the				
		(2)	□ and/or	[II.2.2.2.3.	subjected to collected at	•	sults, carried out on samples late of the commencement o				
	(2)	□ and/or	[II.2.2.3.			gainst those serotypes from were reported during the p					

	II. Health info	ormation									
				State or zo	ne and are w	vithin the im	munity period g	uaranteed in the			
				specification	ons of the va	ccine and					
		(2)	🗆 either	[II.2.2.3.1.	have been v movement]		ore than 60 days	s before the date of	-		
Part II: Certification		(2)	□ and/or	[II.2.2.3.2.	PCR test, wi	ith negative i	results on sample	d vaccine and subj es collected at least e specifications of t	14 days		
rt II: Ceri	(2)	□ and/or	[II.2.2.4.	specific an	have been subjected with positive results to a serological test able to detect specific antibodies against all serotypes 1-24 of infection with bluetongue virus reported during the past 2 years in that Member State or zone and						
Pai		(2)	□ either	[II.2.2.4.1.			oeen carried out of movement]]	on samples collect	ed at least		
		(2)	□ and/or	[II.2.2.4.2.	4.2. the serological test has been carried out on samples collected at leas 30 days before the date of the movement and the animal has been subjected to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of movement;]]]						
	(2)(3) 🗆 and/or	[II.2.2.	virus (sero bluetongu	otypes 1-24) e virus (serc	nor covered otypes 1-24) a	by the eradion of the the by the eradion of the by	cation programn	n infection with blu ne for infection wit wn in Article 32(1)( Ifilled, and they	h		
	(2)	🗆 either	[II.2.2.1.	place of de		d have been	kept protected a	luring transportati gainst attacks by ve			
		(2)	🗆 either	[II.2.2.1.1.	for at least	60 days prio	r to the date of m	novement]]			
		(2)	□ and/or	[II.2.2.1.2.	subjected to samples col	o a serologica llected at lea	al test, with nega st 28 days follow	novement and have tive results, carried ing the date of the ion against attacks	d out on		
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at	o a PCR test, least 14 day	with negative re	novement and have sults, carried out or ate of the commen by vectors;] ]]	n samples		
	(2)	□ and/or	[II.2.2.2.	establishm centred on requireme	nent situated a the establish ents laid down	in a Membe hment, wher n in Sections	r State or in an a re surveillance in a 1 and 2 of Chap	o departure in an rea of at least 150 k compliance with t ter 1 of Part II of Ar d out during that p	he nnex V to		
		(2)	□ either	[II.2.2.2.1.	24 of infect the past 2 y place where	ion with blue ears in an ar e the animal	etongue virus wh ea of at least 150 s were kept and	st those serotypes f nich were reported ) km radius centred are within the imm of the vaccine and	during l on the		
			(2)	🗆 either	[II.2.2.2.1.1.	have been v of moveme		than 60 days befor	e the date		
			(2)	□ and/or	[II.2.2.2.1.2.	have been v subjected to collected at	vaccinated with a of a PCR test, with	an inactivated vacc negative results on er the onset of the ne vaccine;]]]]	n samples		
		(2)	□ and/or	[II.2.2.2.2.	24 of infect the past 2 y	ion with blue ears in an ar	etongue virus wł	ist those serotypes nich were reported ) km radius centred	during		

II. Booth information       (2)       • either       [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 50 days before the date of movement]]         (2)       • or       [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected at lease 30 days before the date of the movement and the application of the analysis of the movement is and the subjected with positive results carried out on samples collected at lease 30 days before the date of movement and the date of movement and the set of origin authorised novement is antimals to another Member State of origin authorised novement is antimis to another Member State of control the Commission and the other Member State of action in factorial state state state. In the Member State of a control (EU) 2020(689 and the competent authority of the Member State of action is referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and (c))         (2)       either       III.2.2.1.       point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       III.2.2.1.4. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and <td< th=""><th>_</th><th>-</th><th colspan="5"></th><th></th><th><u> </u></th></td<>	_	-							<u> </u>		
Image: Second			II. Health info	ormation							
1000000000000000000000000000000000000	rtification				(2)	∘ either	[II.2.2.2.2.1.	a serological test carried out on samples collected at lea			
(2)       □ either       [II.2.2.1.]       with the status free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State state state submitted subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       □ either       [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       □ and/or       [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       □ and/or       [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       □ and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       □ and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and         (2)       □ and/or       [II.2.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State stat such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       □ and/or       [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to		eruncation			(2)	0 or	[II.2.2.2.2.2.	a serological test carried out on samples collected at lea 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of			
the Member State of destination has informed the commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       either       [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020(688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled.]]]         (2)       and/or       [II.2.2.2.4) with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of Astat Such Novement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and         (2)       either       [II.2.2.2.2]       point 5 of Section		Part II: C		[II.2.2.	Part II of A State of or	nnex V to R	nnex V to Regulation (EU) 2020/689 and the competent authority of th				
L       Delegated Regulation, and         (2)       and/or       [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States that such movement is authorised subject to the conditions referred to in Article 32(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(688 and         (2)       either       [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and			(2)	□ either	[II.2.2.1.	the Memb Member S referred to	er State of de tates that suc	estination has informed the Commission and the other ch movement is authorised subject to the conditions	1		
(2)       and/or       [II.2.2.1.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.1.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.       with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       either       [II.2.2.2.1.       point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.3.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [				(2)	□ either	[II.2.2.1.1.					
Part of the second s				(2)	□ and/or	[II.2.2.1.2.	-	-			
Delegated Regulation, and         the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]         (2)       and/or       [II.2.2.2.       with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       either       [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation are fulfilled;]]]         (2)       and/or </td <th></th> <td></td> <td></td> <td>(2)</td> <td>□ and/or</td> <td>[II.2.2.1.3.</td> <td></td> <td></td> <td></td>				(2)	□ and/or	[II.2.2.1.3.					
32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]         (2)       and/or       [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and         (2)       either       [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]         (2)       and/or       [II.2.2.3. meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the o				(2)	□ and/or	[II.2.2.1.4.	-	-			
<ul> <li>(serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and</li> <li>(2) □ either [II.2.2.2.1] point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.2] point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.3] point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and</li> <li>(2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]</li> <li>(2) □ and/or [II.2.2.3] neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State stat such movement is authorised</li> <li>(2) □ either [II.2.2.3.] without any conditions, and</li> <li>(2) □ either [II.2.2.3.] without any conditions, and</li> <li>(2) □ and/or [II.2.3.2.] subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/688, and</li> </ul>							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements			
Delegated Regulation, and       (2)       and/or       [II.2.2.2.2.       point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.3.       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.2.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         (2)       and/or       [II.2.2.3.4.       point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]         (2)       and/or       [II.2.2.3.1.       meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member         (2)       either       [II.2.2.3.1.       without any conditions, and         (2) <td< td=""><th></th><td></td><td>(2)</td><td>□ and/or</td><td>[II.2.2.2.</td><td>(serotypes Commission subject to</td><td>1-24) and the ot the condition</td><td>e Member State of destination has informed the her Member States that such movement is authorised is referred to in Article 43(2)(a), (b) and (c) of Delegated</td><td></td></td<>			(2)	□ and/or	[II.2.2.2.	(serotypes Commission subject to	1-24) and the ot the condition	e Member State of destination has informed the her Member States that such movement is authorised is referred to in Article 43(2)(a), (b) and (c) of Delegated			
Cancel and/or       [II.2.2.3.]       point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and         Cancel C				(2)	□ either	[II.2.2.2.1.					
<ul> <li>(2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]</li> <li>(2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised</li> <li>(2) either [II.2.2.3.1. without any conditions, and</li> <li>(2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and</li> </ul>				(2)	$\Box$ and/or	[II.2.2.2.2.					
<ul> <li>Delegated Regulation, and</li> <li>the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]</li> <li>(2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised</li> <li>(2) either [II.2.2.3.1. without any conditions, and</li> <li>(2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and</li> </ul>				(2)	$\Box$ and/or	[II.2.2.2.3.					
<ul> <li>32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]]</li> <li>(2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised</li> <li>(2) either [II.2.2.3.1. without any conditions, and</li> <li>(2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and</li> </ul>				(2)	□ and/or	[II.2.2.2.4.	-	-			
<ul> <li>by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised</li> <li>(2) □ either [II.2.2.3.1. without any conditions, and</li> <li>(2) □ and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and</li> </ul>							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements			
(2)			(2)	□ and/or	[II.2.2.3.	by the erac 24) and the	dication prog e Member St	gramme for infection with bluetongue virus (serotypes 1 ate of destination has informed the Commission and the	l-		
(2)				(2)	🗆 either	[II.2.2.3.1.	without any	y conditions, and			
							subject to th	he conditions referred to in point 5 of Section 1 of Chapt	er		
				(2)	□ and/or	[II.2.2.3.3.			er		

	II. Health info	rmation						(
					2 of Part II o	f Annex V to Delegated Re	gul	ation (EU) 2020/689, and
		(2)	□ and/or	[II.2.2.3.4.		e conditions referred to in f Annex V to Delegated Re	-	oint 7 of Section 1 of Chapter ation (EU) 2020/689, and
- -		(2)	[II.2.2.3.5.		e conditions referred to in f Annex V to Delegated Re		oint 8 of Section 1 of Chapter ation (EU) 2020/689, and	
Part II: Certification					32(2) of Dele	nents laid down in Article gated Regulation (EU) 202 A Article 33 of that Delegat	20/6	88 and the requirements
မီ	$\mathbf{J}_{\mathbf{H}}^{\mathbf{S}}$ II.3 To the best of my knowledge and as declared by the operator:							
Part II		II.3.1.				patch there are no abnor nimals to be moved.	mal	mortalities with an
		II.3.2.				ct with animals which are 1., or with animals of a low		,
		II.3.3.	not pose a		risk at the cor	nce plan of the confined e nfined establishment of de		blishment, the animals do nation for the spread of
	II.4.	-	ents are ma 1 (EU) 2020/6	-	ort the consig	gnment in accordance with	h A	rticle 4 of Delegated
	II.5.	This certificate is valid for 10 days from the date of issuing. In the case of transport by waterway/sea of animals, the period of 10 days for the validity of the certificate may be extended by the duration of the journey by waterway/sea.						
(2) either • [II.6 Bovine animals from vaccination zone I in relation to emergency protective vaccination ag lumpy skin disease, in compliance with Article 13(2) of, and Annex IX, Part 3, point (3.1), to Commission Del Regulation (EU) 2023/361.]								
	skin diseas		iance with A			lation to emergency protec x IX, Part 3, point (3.2), to (		e vaccination against lumpy nmission Delegated
	Animal we	lfare attesta	ation					
		ovisions of				h certificate were fit to be 1 the intended journey due		
	Notes:							
	In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Irel from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland / Northern Ireland in conjunction with Annex 2 to that Protocol, references to European Un in this certificate include the United Kingdom in respect of Northern Ireland.							ar Article 5(4) of the
	This animal health certificate shall be completed according to the notes for the completion of certificates provi for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.						on of certificates provided	
	Part I:							
	Box reference I.11:	eference of Regulation (EU) 2016/429.						
	Box reference I.12:		lestination": lation (EU) 2		confined estal	plishment approved in acc	cord	lance with Articles 97 and
	Part II:							
	(1)	There can	be one or m	ore animals	s in the consig	gnment.		
	(2)	Delete if n	ot applicabl	e.				

	II. Health information		
	(3) Only in case of animals belonging to the famil Giraffidae, Moschidae or Tragulidae.	ies Antilocapridae, Bovidae, C	amelidae, Cervidae,
	Certifying Officer/Official veterinarian		
	Name (in capital letters)	Qualification and title	
	Date of signature	Signature	
Part II: Certification	Stamp		
ica			
irtif			
: Ce			
τII			
Par			